文献速递淋巴瘤

选择性PI3Kδ抑制剂leniolisib长期治疗成人活化PI3Kδ综合征

Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.
PubMed 文献 · Blood Adv · 2024-01-01

本文报告原始剂量探索试验中6例成人活化PI3Kδ综合征(APDS)患者接受leniolisib治疗6年随访结果。观察到健康相关生活质量改善、淋巴细胞亚群持续改善、临床表现在第2年后减轻,83例不良事件中90.36%为1级,无4/5级或与leniolisib相关的不良事件。

要点

  • 6例成人APDS患者接受leniolisib长期治疗,随访6年。
  • 6例中5例体力活动和社会交往增加、处方药物减少。
  • 过渡型B细胞均值从38.17%降至2.47%,CD4:CD8 T细胞比值正常化至1.11。

核心结论

  • 观察到健康相关生活质量改善以及淋巴细胞亚群和临床表现的持久变化,进一步支持leniolisib作为APDS长期治疗选择。

研究设计与样本

  • 来自原始剂量探索试验中6例成人APDS患者的6年随访,使用正在进行的开放标签扩展研究数据,后期时间点由研究者补充,包括通过临床医生报告问卷评估的健康相关生活质量(HRQoL)。
  • 试验注册于www.ClinicalTrials.gov,编号#NCT02859727。

主要发现

  • 6例患者中5例体力活动和社会交往增加、处方药物减少。
  • 所有患者免疫亚群改善:过渡型B细胞均值从38.17%降至2.47%,CD4:CD8 T细胞比值正常化至1.11。
  • leniolisib暴露前及第一年内出现的感染和胃肠道疾病等表现在第2年后减轻,至第6年新发情况很少。
  • 第6年时半数患者仍存在血小板减少或淋巴细胞减少。
  • 至第5年共83例不良事件,其中90.36%为1级,无4级/5级事件,也无事件被认为与leniolisib相关。

临床怎么用

  • 原文结论支持leniolisib作为APDS长期治疗选择,未给出具体用药推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) is an inborn error of immunity that manifests as immune deficiency and dysregulation; symptoms include frequent infections and lymphoproliferation. In our dose-finding and phase 3 placebo-controlled trials, treatment with the selective PI3Kδ inhibitor leniolisib reduced lymphoproliferation and normalized lymphocyte subsets. Here, we present 6 years of follow-up from the 6 adult patients in the original dose-finding trial receiving leniolisib. We used data from the ongoing open-label extension study, which was supplemented at later time points by investigators, including health-related quality of life (HRQoL) assessed through a clinician-reported questionnaire. We observed improvements in HRQoL: 5 of 6 patients experienced an increase in physical capabilities and socialization, and a decrease in prescribed medications. Immune subsets improved in all patients: mean transitional B-cell levels decreased from 38.17% to 2.47% and the CD4:CD8 T-cell ratio normalized to 1.11. Manifestations seen before and within the first year of leniolisib exposure, such as infections and gastrointestinal conditions, attenuated after year 2, with few new conditions emerging out to year 6. Thrombocytopenia or lymphopenia remained present in half of patients at year 6. Of 83 adverse events through year 5, 90.36% were grade 1; none were grade 4/5 nor deemed leniolisib related. Collectively, we saw an enhancement in HRQoL as well as durable changes in lymphocyte subsets and clinical manifestations, further supporting the use of leniolisib as a long-term therapeutic option for the treatment of APDS. This trial was registered at www.ClinicalTrials.gov as #NCT02859727.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rao VK, Kulm E, Grossman J, et al. Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome. Blood Adv. 2024. PMID: 38593221. doi:10.1182/bloodadvances.2023011000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。